Trxade health, Inc files its 3Q 10Q
TRxADE HEALTH, INC. (NASDAQ: MEDS) filed its Quarterly Report on Form 10-Q for the period ended September 30, 2023, regaining compliance with Nasdaq Listing Rule 5250(c)(1) after receiving a notice of noncompliance. The parent company of a pharmaceutical business-to-business exchange platform, TRxADE, believes it has addressed the issue.
Negative
The company received a notice of noncompliance from the Nasdaq Listing Qualifications Department, indicating a lack of timely filing of its Form 10-Q, which affected its compliance with Nasdaq Listing Rule 5250(c)(1).
The recent filing of the Form 10-Q by TRxADE HEALTH, INC. signifies a critical step in maintaining the company's status on the NASDAQ stock exchange. The delay in filing had previously put the company at risk of noncompliance with the stringent requirements of Nasdaq Listing Rule 5250(c)(1). This rule mandates that all listed companies must file periodic financial reports in a timely manner. The breach of this rule had potential implications for investor confidence and the stock's liquidity, as it could lead to trading suspensions or even delisting.
An immediate effect of the filing is likely to be the restoration of investor confidence. The market reacts to uncertainty with volatility and the resolution of a compliance issue can stabilize the stock price. In the longer term, the company's ability to continue meeting filing deadlines will be crucial in demonstrating operational reliability and transparency, which are key qualities assessed by investors. However, it is essential to monitor the company's future compliance, as repeated incidents could signify deeper administrative or financial issues.
In the context of the pharmaceutical industry, regulatory compliance is not merely a legal formality but a cornerstone of corporate credibility. TRxADE HEALTH, INC.'s business-to-business exchange platform operates in a sector where trust and regulatory adherence are paramount. The initial failure to file the Form 10-Q on time may have raised concerns among stakeholders regarding the company's internal processes and governance. Now that compliance has been regained, it will be important to understand the reasons behind the delay and assess whether it was an isolated incident or indicative of systemic issues that could affect future operations.
Furthermore, the company's performance as detailed in the Form 10-Q will be closely scrutinized by investors and competitors alike. The contents of the report, including revenue, expenses and profit margins, will be pivotal in evaluating the company's current market position and strategic direction. Any deviations from industry norms or exceptional results will be of particular interest, as they may signal competitive advantages or challenges.
From a legal standpoint, TRxADE HEALTH, INC.'s adherence to NASDAQ's Listing Rule 5250(c)(1) by filing its overdue Form 10-Q is a move towards rectifying its regulatory standing. The notice of noncompliance from NASDAQ serves as a procedural warning and while it does not immediately affect the company's listing, it highlights the importance of regulatory diligence. The potential legal ramifications of continued noncompliance could include fines, increased scrutiny from the Securities and Exchange Commission (SEC) and the aforementioned risk of delisting.
It is also important to consider the legal obligations the company has to its shareholders. Timely and accurate financial reporting is a key aspect of corporate governance and failure in this domain can lead to shareholder lawsuits, particularly if the stock price is negatively impacted. As the company claims to have regained compliance, the focus will now shift to ensuring that all future filings adhere to the required deadlines to avoid similar legal and financial complications.
01/17/2024 - 09:07 AM
TAMPA, FL, Jan. 17, 2024 (GLOBE NEWSWIRE) -- TRxADE HEALTH, INC. (NASDAQ: MEDS) (“TRxADE”), a parent company of pharmaceutical business-to-business exchange platform, announced today that it filed its Quarterly Report on Form 10-Q for the period ended September 30, 2023 (the “Form 10-Q”).
On November 21, 2023, the Company received a standard notice of noncompliance from the Nasdaq Listing Qualifications Department (“Nasdaq”) indicating that, as a result of not having timely filed its Form 10-Q, the Company was not in compliance with Nasdaq Listing Rule 5250(c)(1), which requires timely filing of all required periodic financial reports with the Securities and Exchange Commission.
The Company believes it has now regained compliance with Nasdaq Listing Rule 5250(c)(1) with the filing of its Form 10-Q.
About TRxADE HEALTH, INC.
TRxADE Health, Inc. is a parent company with various subsidiaries which include the pharmaceutical marketplace https://rx.trxade.com , plant-based food www.superlatus.com .
Forward-Looking Statements
Certain statements in this press release are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Securities Litigation Reform Act of 1995. TRxADE intends that such forward-looking statements be subject to the safe harbors created thereby. Forward-looking statements relate to future events or TRxADE’s future performance or future financial condition. These forward-looking statements are not historical facts but rather are based on current expectations, estimates, and projections about TRxADE, its industry, beliefs, and assumptions. Such forward-looking statements include, but are not limited to, statements regarding TRxADE’s or TRxADE’s management team’s expectations, hopes, beliefs, intentions, or strategies regarding the future, including TRxADE ‘splans for and the potential benefits of the supplier agreement and the products, markets, and expected future performance and market opportunities of TRxADE. In addition, any statements that refer to projections, forecasts, or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. In some cases, you can identify forward-looking statements by the following words: “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “ongoing,” “plan,” “potential,” “predict,” “project,” “should,” or the negative of these terms or other similar expressions, but the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements are subject to a number of risks and uncertainties (some of which are beyond TRxADE’s control) that may cause actual results or performance to be materially different from those expressed or implied by such forward-looking statements. Accordingly, readers should not place undue reliance on any forward-looking statements. These risks include risks relating to agreements with third parties; TRxADE’s ability to raise funding in the future, as needed, and the terms of such funding, including potential dilution caused thereby; TRxADE’s ability to continue as a going concern; security interests under certain of TRxADE’s credit arrangements; TRxADE’s ability to maintain the listing of its common stock on The Nasdaq Capital Market; claims relating to alleged violations of intellectual property rights of others; the outcome of any current legal proceedings or future legal proceedings that may be instituted against TRxADE; unanticipated difficulties or expenditures relating to TRxADE’s business plan; and those risks detailed in TRxADE’s most recent Annual Report on Form 10-K and subsequent reports filed with the Securities and Exchange Commission. Forward-looking statements speak only as of the date they are made. TRxADE undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise that occur after that date, except as otherwise provided by law.
Investor Contact: info@skylineccg.com
What form did TRxADE HEALTH, INC. file for the period ended September 30, 2023?
TRxADE HEALTH, INC. filed its Quarterly Report on Form 10-Q for the period ended September 30, 2023.
What notice did the company receive from Nasdaq?
The company received a standard notice of noncompliance from the Nasdaq Listing Qualifications Department, indicating a lack of timely filing of its Form 10-Q.
What rule did the company violate?
The company was not in compliance with Nasdaq Listing Rule 5250(c)(1), which requires timely filing of all required periodic financial reports with the Securities and Exchange Commission.
What did the company believe it has regained compliance with?
The company believes it has now regained compliance with Nasdaq Listing Rule 5250(c)(1) with the filing of its Form 10-Q.
